Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer.
INTEGRA Biosciences is on track to net zero
INTEGRA Biosciences, a leading provider of liquid handling solutions, is dedicated to accelerating scientific discovery while addressing climate change.
June 28, 2024